Insider Trading & Executive Data
Start Free Trial
189 insider trades in the last year. Go beyond summary counts with transaction-level detail, compensation intelligence, and institutional ownership context.
ESAB Corporation is a global provider of cutting, joining and welding equipment, consumables, gas-control products, robotics and digital/automation solutions serving roughly 150 countries. Organized into Americas and EMEA & APAC segments, the company emphasizes growth via bolt‑on acquisitions (three in 2024 and several more in 2025 filings) and an EBX continuous‑improvement operating model that management cites as a competitive advantage. Financially, ESAB reported modest topline contraction but stronger profitability in 2024 (expanded gross margin to 37.9% and adjusted EBITDA of $528.8M), while facing material exposures from FX, commodity costs, export controls, regulatory requirements for medical gas products, pension and asbestos liabilities, and ~5% revenue from Russia. As a Industrials‑sector / Metal Fabrication‑industry company, ESAB’s performance is cyclical, influenced by raw‑material prices, tariffs and regional demand patterns.
Compensation at ESAB is likely structured to align with industrial peers: fixed salary plus annual cash incentives tied to near‑term financial metrics (adjusted EBITDA, operating margin, revenue or organic growth) and long‑term equity (RSUs, performance shares or options) tied to multi‑year targets like ROIC, free cash flow and total shareholder return. Given management’s emphasis on EBX productivity, pricing actions and acquisition-driven growth, short‑term bonuses and LTIP performance metrics are likely to reward margin expansion, successful integration of bolt‑on acquisitions and cash‑flow generation. Regulatory, asbestos and pension liability risks, plus covenant and leverage considerations (term loans and senior notes outstanding), make cash‑conserving or performance‑contingent pay elements and clawback/forfeiture provisions more probable. Finally, retention awards tied to recent acquisitions and R&D/product milestones are plausible to secure leadership through integration and product development cycles.
Insider trading at ESAB should be interpreted in light of recurring M&A activity, periodic equity vesting and material operational risks (FX, tariffs, commodity swings, asbestos litigation and regulatory clearances) that can quickly change outlooks. Typical patterns to monitor: post‑earnings trades around adjusted EBITDA/margin beats, sales following equity vesting or retention grants tied to acquisitions, and opportunistic buys by executives after declines that reflect confidence in integration or margin recovery. Regulatory restrictions (Section 16 reporting, blackout windows, 10b5‑1 plans) and the company’s debt/covenant profile may also shape timing and size of trades; unusually timed insider activity around material disclosures (Russia exposure, major acquisitions, FDA/EU medical approvals, or pension/asbestos developments) warrants closer scrutiny.